News Center

  • All
  • Pipeline
  • Products

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and…

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and…

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.…

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) — Myriad…

SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

Prolaris One of Only Two Prognostic Tests Recommended for Expanded Indications SALT LAKE CITY, March 18, 2020 (GLOBE NEWSWIRE) — Myriad…

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy SALT LAKE…

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer SALT LAKE CITY, Feb. 11,…

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer SALT LAKE CITY, Jan. 22, 2020…

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer SALT LAKE CITY, Jan.…

New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study SALT LAKE CITY, Jan. 06,…

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer…

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes New Clinical…

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening SALT LAKE CITY, Dec. 04,…

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium SALT LAKE CITY, Dec.…

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis SALT LAKE…

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy Clinical Study…

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis Vectra Test Predicts Radiographic Progression…

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SALT LAKE CITY, Nov. 01, 2019 (GLOBE…

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28,…

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE CITY, Oct. 08,…

Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer…

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for…

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Assessment…

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate…

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men…

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated…

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology…

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) NCCN Guidelines Recommend…

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Study Finds…

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer New Study Finds Many Women May Receive Unnecessary…

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test myChoice HRD Is…

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men…

Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib Myriad Will Seek FDA…

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated…

EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major Milestone in Expanding Access…

Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE)…

EndoPredict is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemotherapy and Who Can…